Posted on April - 22 - 2010
Verilast knee wins FDA approval
The U.S. Food and Drug Administration has cleared Smith & Nephew to market a 30-year artificial knee.
The Memphis Orthopaedics Division said Thursday its Verilast technology, when used on Legion brand knee replacement, achieved an 81 percent reduction in wear during a simulation of 30 years of physical activity. The FDA clearance enables the company to expand claims for a product previously touted as offering reduced wear.
“Physically active patients want to end their knee pain for good,” said Joseph M. DeVivo, president of Smith & Nephew Orthopaedics. “We’re working to make knee implants that last a lifetime — that’s our goal, and we’ve validated Verilast technology out to 30 years for a market that views 10 to 15 years as the gold standard.”
Verilast combines Smith & Nephew’s Oxinium brand metal alloy with a crosslinked polyethylene material called XLPE.
Similar Posts:
- DeVivo is out as president of Memphis-based Smith & Nephew Orthopaedic
- Smith & Nephew has stepped up to be the presenting sponsor of the St. Jude Classic
- AstraZeneca drug wins US approval
- Christ Community Health Services gets loan help from IDB, First Tenn.
- Four Northeast Ohio institutions receive $2.7 million grant for heart failure study
